High Quality Evidence of Chinese Lupus Nephritis (HELP)
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 5,000
- 试验地点
- 2
- 主要终点
- All-cause mortality and cardiovascular mortality of LN patients
研究概览
简要总结
The investigators are registering LN patients at recruited hospitals and developing a LN database in China. Patients will be follow-up every year, and both baseline and follow-up information will be entered into the registration system.
详细描述
The investigators are registering Lupus nephritis (LN) and developing a LN database in China. Patients' demographic characteristics (including age, gender, height, weight, BMI, smoking, drinking, and education etc.), clinical characteristics (including systolic blood pressure, diastolic blood pressure, and lab measurements of whole blood, serum, urine etc.), complications, drug information at the baseline will be collected. Patients will be follow-up every year, the demographic and clinical characteristics, complications; drug information of patients will be collected at each visit. We will also record the outcome at each visit, such as mortality (including all-cause mortality and cardiovascular disease mortality), end-stage renal disease (ESRD) or serum creatinine doubling. The patient survival and renal survival will be compared using the LN database.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 14 Years 至 —(Child, Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who diagnosis as lupus nephritis
排除标准
- 未提供
研究组 & 干预措施
LN patients
Patients diagnosis as lupus nephritis
干预措施: No Intervention (Other)
结局指标
主要结局
All-cause mortality and cardiovascular mortality of LN patients
时间窗: 10years
A composite renal outcome of LN patients
时间窗: 10years
The composite renal outcome defined as doubling of serum creatinine and ESRD (defined as initiation of dialysis or kidney transplantation).
次要结局
未报告次要终点
研究者
Xue Qing Yu
Professor
Sun Yat-sen University
